Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Limited stage I disease i… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma.

Artikel i vetenskaplig tidskrift
Författare Andishe Attarbaschi
Georg Mann
Angelo Rosolen
Denise Williams
Anne Uyttebroeck
Ildiko Marky
Laurence Lamant
Keizo Horibe
Grazyna Wrobel
Auke Beishuizen
Wilhelm Wössmann
Alfred Reiter
Audrey Mauguen
Marie-Cecile Le Deley
Laurence Brugières
Publicerad i Blood
Volym 117
Nummer/häfte 21
Sidor 5616-9
ISSN 1528-0020
Publiceringsår 2011
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Sidor 5616-9
Språk en
Länkar dx.doi.org/10.1182/blood-2010-12-32...
Ämnesord Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Child, Female, Humans, International Agencies, Lymphoma, Large-Cell, Anaplastic, drug therapy, mortality, pathology, Male, Neoplasm Staging, Prognosis, Prospective Studies, Survival Rate
Ämneskategorier Cancer och onkologi

Sammanfattning

Data on incidence, characteristics, and prognosis in stage I childhood anaplastic large cell lymphoma are scarce. Of 463 patients enrolled in the international ALCL99 trial, 36 (8%) had stage I disease and were treated with a prephase chemotherapy, followed by either 3 chemotherapy courses in case of initial complete resection (6 patients) or otherwise by 6 courses of chemotherapy (30 patients). Disease localization was to the peripheral lymph nodes in 26, soft tissue mass in 8, and solitary bone and bronchial disease in 1 patient each. Of the 6 patients with complete resection, none experienced relapse, whereas of the 30 remaining stage I patients, 9 (30%) relapsed, including in all cases a new site of disease involvement and including 3 of 5 anaplastic lymphoma kinase-negative patients. In summary, the failure rate for incompletely resected stage I disease was similar to that for patients with stage II and stage III/IV disease. Whether anaplastic lymphoma kinase negativity contributed to this moderate outcome has to be proven prospectively. This study was registered at www.clinicaltrials.gov as NCT00006455.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?